Table 3.
Characteristics of Participants With SARS-CoV-2 Variants of Concern (n=19), Hospital Israelita Albert Einstein, São Paulo, Brazil, from January 1, 2021, to August 3, 2021 a
| SARS-CoV-2 Variant of Concern |
Date | Age, y | Sex | Job Type | COVID-19 Vaccine |
Hospitalization | ICU | Mechanical Ventilation | Death |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 3/20/2021 | 37 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 3/21/2021 | 33 | Female | DPF | CoronaVac | No | … | … | No |
| B.1.1.7 | 3/25/2021 | 26 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 3/25/2021 | 46 | Male | DPF | CoronaVac | No | … | … | No |
| P1 | 3/26/2021 | 30 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 4/5/2021 | 48 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 4/26/2021 | 43 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 4/27/2021 | 42 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 5/4/2021 | 42 | Female | NDPC | CoronaVac | No | … | … | No |
| P1 | 5/10/2021 | 35 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 5/12/2021 | 51 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 5/17/2021 | 39 | Male | DPF | CoronaVac | Yes | No | No | No |
| P1 | 5/31/2021 | 37 | Female | NDPC | ChAdOx1 | No | … | … | No |
| P1 | 6/2/2021 | 42 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 6/3/2021 | 37 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 6/4/2021 | 44 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 6/4/2021 | 31 | Female | DPF | CoronaVac | No | … | … | No |
| P1 | 6/5/2021 | 44 | Female | DPF | ChAdOx1 | No | … | … | No |
| P1 | 6/7/2021 | 27 | Female | DPF | CoronaVac | No | … | … | No |
Note. P1, γ (gamma) variant; B.1.1.7, α variant; ChAdOx1, Oxford-AstraZeneca vaccine; DPC, direct patient facing; NDPC, no direct patient contact.
a
The whole-genome sequencing was performed from March to June 20